Hannah E. Goulart, MD
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Leukemia, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2020 | The George Washington University, Washington, DC, US, Doctor of Medicine |
| 2014 | Northeastern University, Boston, MA, US, Biology, Bachelor of Science |
Postgraduate Training
| 2023-2026 | Hematology Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2021-2023 | Internal Medicine Resident, Internal Medicine, The Mount Sinai Hospital, New York, New York |
| 2020-2021 | Internal Medicine Intern, Internal Medicine, The Mount Sinai Hospital, New York, New York |
Licenses & Certifications
| 2023 | American Board of Internal Medicine Board Certifcation |
Experience & Service
Administrative Appointments/Responsibilities
MD Anderson Chief Fellow for Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2026
MD Anderson Chief Fellow for UT Resident Education, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2024
Other Professional Positions
Clinical Research Coordinator (CRC) II, Massachusetts General Hospital, Boston, MA, 2014 - 2016
Clinical Research Assistant, Tufts Medical Center, Boston, MA, 2013 - 2013
Neurobiology Research Assistant, Harvard Medical School, Boston, MA, 2012 - 2014
Intramural Institutional Committee Activities
Co-Chair, Hematology/Oncology Fellowship Wellness Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2026
Member, Hospital Workgroup Committee, Icahn School of Medicine at Mount Sinai Hospital, 2022 - 2023
Member, Alpha Omega Alpha Selection Committee, Icahn School of Medicine at Mount Sinai Hospital, 2021 - 2023
Secretary, Mount Sinai ASCO Interest Group Committee, Icahn School of Medicine at Mount Sinai Hospital, 2021 - 2022
Instructor, Student Educator, TALKS, The George Washington University School of Medicine and Health Sciences, 2019 - 2020
Co-President, Internal Medicine Interest Group, The George Washington University School of Medicine and Health Sciences, 2017 - 2018
Co-Chair, Orientation Co-Chair for Class of 2021, The George Washington University School of Medicine and Health Sciences, 2017 - 2017
Representative, Learning Community, The George Washington University School of Medicine and Health Sciences, 2016 - 2020
Honors & Awards
| 2026 | EHA Travel Grant, European Hematology Association |
| 2026 | 2026 Conquer Cancer Merit Award, American Society of Clinical Oncology |
| 2025 | American Society of Hematology Abstract Achievement Award, The American Society of Hematology |
| 2024 | Young Hematology Scholar Award for the 2024 Summit on Hematological Cancers, Binaytara Foundation |
| 2024 | Clifton D. Howe Award for Clinical Excellence in Oncology, The University of Texas MD Anderson Cancer Center |
| 2022 | Resident of the Month Nomination, The Mount Sinai Hospital |
| 2020 - Present | Alpha Omega Alpha, Alpha Omega Alpha Honor Medical Society |
| 2017 - 2018 | GW Endowed Scholarship for Academic Performance, The George Washington University |
| 2014 | Summa cum laude, Northeastern University |
| 2009 - 2014 | Northeastern University College of Science Dean's List, Northeastern University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. A Phase I/II Trial of Tagraxofusp, Hyper-CVAD, and Venetoclax for Patients with Newly Diagnosed or Relapsed/Refractory BPDCN. Invited. MD Anderson Division of Cancer Medicine Grand Rounds. Houston, Texas, US.
- 2026. A Propensity Score Analysis of Hyper-CVAD versus Hyper-CVAD in Combination with Blinatumomab for Patients with Newly Diagnosed Philadelphia-Chromosome Negative B-Cell Acute Lymphoblastic Leukemia. Invited. MD Anderson Division of Cancer Medicine Grand Rounds. Houston, Texas, US.
- 2018. Predictive Value of Pulmonary Function Testing in Evaluation of Pulmonary Hypertension in Sarcoidosis. GW Research Days. Washington, DC, US.
Regional Presentations
- 2025. Clinical Trial Endpoints and Outcomes in MF: Time for a Change or Keep the Status Quo?. Invited. 6th Annual MPN MDS Focus Meeting. Austin, TX, US.
National Presentations
- 2026. Revumenib as Maintenance for Patients with AML following Allogenic Stem Cell Transplantation. Invited. ASCO. Alexandria, Virginia, US.
- 2025. Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2025. Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2025. Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2025. Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2025. Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders. Poster. Washington, District of Columbia, US.
- 2025. Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2025. The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2025. Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2025. Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2025. Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Poster. ASH 67th Annual Meeting. Washington, District of Columbia, US.
- 2024. Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia. Poster. ASH 66th Annual Meeting. San Diego, CA, US.
- 2024. A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia Program: Oral and Poster Abstracts. Poster. ASH 66th Annual Meeting. San Diego, CA, US.
- 2024. Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations. Poster. ASH 66th Annual Meeting. San Diego, CA, US.
- 2024. A Case Report of Oral Decitabine in Combination with Venetoclax as a Bridging Modality for a Patient in First Complete Remission with BPDCN Awaiting Allogeneic Stem Cell Transplant. Poster. 2024 Summit on Hematological Cancers. Nashville, TN, US.
- 2023. Do Hematologic Parameters Predict Thrombosis or Disease Transformation in Essential Thrombocythemia?. Poster. ASH 65th Annual Meeting. San Diego, CA, US.
- 2018. Discrepancies in Epworth Sleepiness Scale after treatment of OSA according to race and patient characteristics. SLEEP 2018. Baltimore, MD, US.
- 2018. Predictive Value of Pulmonary Function Testing in Evaluation of Pulmonary Hypertension in Sarcoidosis. American Thoracic Society 2018 International Conference. San Diego, CA, US.
Grant & Contract Support
| Date: | 2026 - 2027 |
| Title: | A Phase II Trial of the Bruton Tyrosine Kinase Degrader BGB-16673 in combination with BCL-2 inhibitor Sonrotoclax for patients with treatment-naïve chronic lymphocytic leukemia |
| Funding Source: | ASCO |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Investigating monocyte differentiation dynamics and inflammatory signaling output in response to anti-CSF1R treatment with axatilimab in myelofibrosis |
| Funding Source: | ASCO Conquer Cancer Foundation Young Investigator Award |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Jabbour E, Rausch CR, Goulart H, Jain N, Ravandi F, Maiti A, Alvarado Y, Burger J, Yilmaz M, Khouri I, Kebriaei P, Jorgensen J, Wang SA, Wang X, Mayor E, Garris RS, Short NJ, Kantarjian H. Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia. Blood Cancer J. e-Pub 2026. PMID: 42365008.
- Jabbour E, Goulart H, Sasaki K, Rausch CR, Jain N, Kadia TM, DiNardo C, Daver N, Pemmaraju N, Ravandi F, Montalban-Bravo G, Garcia-Manero G, Hammond D, Swaminathan M, Hachem M, Khouri R, Ohanian M, Garris R, Short NJ, Kantarjian HM. Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis. Am J Hematol 101(7):1729-1736, 2026. e-Pub 2026. PMID: 42035233.
- Sasaki K, Kantarjian H, Rausch CR, Goulart H, Jain N, Huang X, Hachem M, Wierda WG, Kadia TM, Borthakur G, Issa GC, Alvarado Y, Pemmaraju N, Garris R, Ravandi F, Garcia-Manero G, Short NJ, Jabbour E. Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Am J Hematol 101(7):1717-1722, 2026. e-Pub 2026. PMID: 42031676.
- Goulart H, Braish J, Short NJ, Jain N, Sasaki K, Kantarjian H, Jabbour EJ. A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia Positive Acute Lymphoblastic Leukemia. Acta Haematol, 2026. e-Pub 2026. PMID: 41915597.
- Goulart H, Short NJ, Borthakur G, Jain N, DiNardo CD, Loghavi S, Khouri R, Rita Hachem MC, Ravandi F, Daver NG, Kadia TM, Yilmaz M, Issa GC, Bazinet A, Swaminathan M, Montalban-Bravo G, Haddad FG, Garris R, Kantarjian HM, Jabbour E. Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia. Blood Adv, 2026. e-Pub 2026. PMID: 41860396.
- Goulart H, Ravandi F, Short NJ, Jain N, Daver N, Kadia TM, DiNardo C, Borthakur G, Takahashi K, Pemmaraju N, Haddad FG, Bravo GM, Alvarado Y, Issa GC, Bataller A, Pierce S, Loghavi S, Tang G, Wang SA, Thakral B, Shpall E, Champlin R, Khouri I, Kebriaei P, Garcia-Manero G, Sasaki K, Jabbour E, Senapati J. Clinical Outcomes of Adult Patients with Newly Diagnosed Mixed Phenotype Acute Leukemia. JCO PO, 2025. e-Pub 2025. PMID: 41370732.
- Goulart H, Jabbour E, Short N, Jain N, Issa G, Atluri H, Bataller A, Kadia T, Daver N, DiNardo C, Garris R, Senapati J, Ravandi F, Kantarjian H. Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens. Am J Hematol 100(11):2128-2133, 2025. e-Pub 2025. PMID: 40862325.
- Azevedo RS, Fayad L, Kanagal-Shamanna R, Loghavi S, Hu S, Bueso-Ramos CE, Sasaki K, Abuasab T, Khawaja F, Goulart H, Abou Dalle I, Borthakur G, Pemmaraju N. Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation. Leuk Lymphoma 66(10):1947-1951, 2025. e-Pub 2025. PMID: 40440732.
- Goulart H, Garcia-Manero G, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qazilbash M, Rausch C, Llaurador Caraballo G, Pierce S, Pemmaraju N. A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm. Leuk Lymphoma 66(9):1727-1730, 2025. e-Pub 2025. PMID: 40304131.
- Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
- Goulart H, Elmore K, Scelsa S, Park D, Keyzner A, Ibrahim U. CAR T cell therapy-related lumbosacral polyradiculopathy with myelitis and stiff person syndrome with response to intravenous immunoglobulin and corticosteroids in a patient with acute lymphoblastic leukemia. Hematol Transfus Cell Ther 47(3):103932, 2025. e-Pub 2025. PMID: 40639061.
- Goulart H, Jabbour E, Short NJ, Kadia TM, Pemmaraju N, Takahashi K, Ravandi F, Konopleva M, Jain N. A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk, 2025. e-Pub 2025. PMID: 40500616.
- Edelman Saul E, Urrutia S, Yang H, Montalban-Bravo G, Tang G, Toruner G, Patel K, Luthra R, Bueso-Ramos C, Wang SA, Chien K, Sasaki K, Atluri H, Goulart H, Thakral B, Garcia-Manero G, Kanagal-Shamanna R. A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping. J Natl Compr Canc Netw 23(6), 2025. e-Pub 2025. PMID: 40345240.
- Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Alvarado Y, Atluri H, Yilmaz M, Haddad FG, Marx KR, Rausch C, Loghavi S, Jain N, Garcia-Manero G, Ravandi-Kashani F, Kadia TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. Cancer 131(8):e35840, 2025. e-Pub 2025. PMID: 40193193.
- Glass LN, Sumon M, Goulart H, Ahari J. Disappearing nodules: spontaneously regressing pulmonary amyloidosis. BMJ Case Rep 12(5), 2019. e-Pub 2019. PMID: 31110070.
- Hariri LP, Adams DC, Wain JC, Lanuti M, Muniappan A, Sharma A, Colby TV, Mino-Kenudson M, Mark EJ, Kradin RL, Goulart H, Suter MJ. Reply to Wijmans et al.: Optical Coherence Tomography: A Valuable Novel Tool for Assessing the Alveolar Compartment in Interstitial Lung Disease?. Am J Respir Crit Care Med 197(9):1232-1233, 2018. e-Pub 2018. PMID: 29244521.
- Montesi SB, Rao R, Liang LL, Goulart HE, Sharma A, Digumarthy SR, Shea BS, Seethamraju RT, Caravan P, Tager AM. Gadofosveset-enhanced lung magnetic resonance imaging to detect ongoing vascular leak in pulmonary fibrosis. Eur Respir J 51(5), 2018. e-Pub 2018. PMID: 29622569.
- Hariri LP, Adams DC, Wain JC, Lanuti M, Muniappan A, Sharma A, Colby TV, Mino-Kenudson M, Mark EJ, Kradin RL, Goulart H, Tager AM, Suter MJ. Endobronchial Optical Coherence Tomography for Low-Risk Microscopic Assessment and Diagnosis of Idiopathic Pulmonary Fibrosis In Vivo. Am J Respir Crit Care Med 197(7):949-952, 2018. e-Pub 2018. PMID: 28934552.
- Jose A, Delio J, Gwizdala J, Goulart H, Ahari JE. Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 35(4):308-316, 2018. e-Pub 2018. PMID: 32476918.
- Glass LN, Goulart H, Mortman KD, Ahari J. Pleural lipoma clinically mimicking the presentation of superior sulcus tumour upon initial evaluation. BMJ Case Rep 2017, 2017. e-Pub 2017. PMID: 29222220.
Review Articles
- Short NJ, Ribera J, Dalle IA, Goulart H, Ribera J, Mohty M, Torrent A, Bazarbachi A. Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL. Am Soc Clin Oncol Educ Book 46(3), 2026. e-Pub 2026. PMID: 42102341.
- Goulart H, Masarova L, Pemmaraju N, Bose P. A pharmacological profile of pacritinib for the treatment of myelofibrosis. Expert Rev Clin Pharmacol 19(5):409-418, 2026. e-Pub 2026. PMID: 41949314.
- Goulart H, Loghavi S. Molecular Pathology of Myeloid Neoplasms. Surg Pathol Clin 19(2):213-225, 2026. e-Pub 2026. PMID: 42091270.
- Goulart H, Jabbour E. SOHO State of the Art Updates and Next Questions | SOHO 2025 Next Questions: Acute Lymphoblastic Leukemia. CLML, 2026. e-Pub 2026. PMID: 41582075.
- Goulart H, Wei AH, Kadia TM. Maintenance Therapy in AML: What Is the Future Potential?. Am J Hematol 100 Suppl 2:38-49, 2025. e-Pub 2025. PMID: 39960005.
- Goulart H, Kantarjian H, Pemmaraju N, Daver N, DiNardo CD, Rausch CR, Ravandi F, Kadia TM. Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. Blood Cancer Discov 6(1):23-37, 2025. e-Pub 2025. PMID: 39565177.
- Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian JJ, Pemmaraju N. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. Br J Haematol 205(1):48-60, 2024. e-Pub 2024. PMID: 38853641.
- Goulart H, Mascarenhas J, Tremblay D. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions. Ann Hematol 101(5):935-951, 2022. e-Pub 2022. PMID: 35344066.
Other Articles
- Goulart H, Sastow D, Moshier E, Martin L, Mascarenhas J, Tremblay D Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement. Leuk Res 137:107452, 2024. PMID: 38335816.
Patient Reviews
CV information above last modified August 06, 2026